Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04740671




Registration number
NCT04740671
Ethics application status
Date submitted
2/02/2021
Date registered
5/02/2021
Date last updated
17/04/2024

Titles & IDs
Public title
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD
Scientific title
A Phase 3, Randomized, Double-masked, Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age-related Macular Degeneration (wAMD)
Secondary ID [1] 0 0
HLX04-O-wAMD
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Age Related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - HLX04-O
Treatment: Drugs - ranibizumab

Experimental: HLX04-O - Biologic recombinant anti-VEGF humanized monoclonal antibody

Active Comparator: Ranibizumab - Biologic anti-VEGF recombinant humanized monoclonal antibody fragment


Treatment: Drugs: HLX04-O
Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.

Treatment: Drugs: ranibizumab
Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean change from baseline in BCVA at at Week 36
Timepoint [1] 0 0
up to at Week 36
Secondary outcome [1] 0 0
Key Secondary Outcome : Mean change from baseline in BCVA at Week 48.
Timepoint [1] 0 0
up to Week 48
Secondary outcome [2] 0 0
Mean change in BCVA over time
Timepoint [2] 0 0
up to Week 48
Secondary outcome [3] 0 0
Proportion of patients gaining at least 15 letters in the BCVA at Week 12, 24, 36 and 48
Timepoint [3] 0 0
up to Week 12, 24, 36 and 48
Secondary outcome [4] 0 0
Proportion of patients gaining at least 10 letters in the BCVA at Week 12, 24, 36 and 48
Timepoint [4] 0 0
up to Week 12, 24, 36 and 48
Secondary outcome [5] 0 0
Proportion of patients gaining at least 5 letters in the BCVA at Week 12, 24, 36 and 48
Timepoint [5] 0 0
up to Week 12, 24, 36 and 48
Secondary outcome [6] 0 0
• Mean change from baseline in size of CNV and total area of fluorescein leakage from CNV on FA at Week 12, 36 and 48 (as measured by the Reading Center)
Timepoint [6] 0 0
up to Week 12, 36 and 48
Secondary outcome [7] 0 0
• Mean change from baseline in CRT on OCT at Week 12, 24, 36 and 48 (as measured by the Reading Center)
Timepoint [7] 0 0
up to week 12, 24, 36 and 48
Secondary outcome [8] 0 0
Change from baseline in NEI VFQ-25 scale score at Week 12, 36, and 48.
Timepoint [8] 0 0
up to Week 12, 36, and 48

Eligibility
Key inclusion criteria
1. Capable to understand and sign the informed consent form (ICF) which includes
compliance with the requirements and restrictions listed in the ICF and in this
protocol.

2. Women or men aged =50 years when signing the ICF.

3. In the Investigator's judgment, willing and able to complete all visits and
assessments adhering to the prohibitions and restrictions specified in this protocol.

4. Newly diagnosed, untreated, active CNV lesions secondary to age-related macular
degeneration that affect the central subfield (CSF) in the study eye. Active CNV was
defined as leakage on fluorescein angiography (FA) and subretinal or intraretinal
fluid on optical coherence tomography (OCT) with confirmation of the reading center
during screening.

5. The total lesion area (including hemorrhage, scar and neovascularization) of the study
eye =12 disc area (DA) with confirmation of the reading center before randomization

6. The BCVA letters between 24 and 73, inclusive, in the study eye, using Early Treatment
Diabetic Retinopathy Study (ETDRS) charts.

7. Participants' fellow (non-study) eye must have a BCVA of 24 letters or better.

8. Clear ocular media and adequate pupillary dilatation to allow acquisition of good
quality retinal images to confirm the diagnosis.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis or
atrophy involving the fovea, or CNV due to other causes in the study eye (e.g., ocular
histoplasmosis, trauma,pathological myopia, etc.) with confirmation of the reading
center.

2. The fellow (non-study) eye needs anti-VEGF IVT injection (e.g. CNV due to wAMD,
trauma, pathological myopia, retina vein occlusion, diabetic macular edema, etc.) in
the next 3 months after randomization, in the investigator's judgment.

3. Aphakia (except intraocular lens) or posterior capsular rupture of the lens (except
yttrium-aluminium-garnet (YAG) laser posterior capsulotomy after intraocular lens
implantation =30 days prior to first dose) in the study eye.

4. Active or recent (within 1 month prior to dose 1) intraocular, extraocular or
periocular infection (including conjunctivitis, keratitis, scleritis or
endophthalmitis), or history of idiopathic or autoimmune-associated uveitis in either
eye.

5. Vitreous hemorrhage in the study eye within 3 months prior to dose 1.

6. Corneal dystrophy or history of corneal transplantation, scleral softening or history
of scleral softening, history of rhegmatogenous retinal detachment or macular hole
(Stage II, III or IV) in the study eye.

7. Uncontrolled glaucoma in the study eye (defined as intraocular pressure [IOP] =25 mmHg
despite treatment with antiglaucoma medication), and/or glaucoma filtering surgery
(e.g., trabeculectomy, scleral nipping, non-penetrating trabeculectomy, etc.)

8. Equivalent spherical diopter of the study eye =-8D. For participants who had undergone
refractive correction or cataract surgery, the equivalent spherical diopter of the
study eye before surgery =-8D.

9. Estimated by the Investigator, any concurrent intraocular condition except wAMD (e.g.,
diabetic retinopathy, dry AMD, retina vein occlusion, uveitis, angioid streaks,
retinal detachment, epiretinal membrane, amblyopia, central serous chorioretinopathy,
etc.) in the study eye that limited the potential to gain visual acuity upon treatment
with the investigational product, or could have required medical or surgical
intervention during the study to prevent or treat visual loss.

10. Underwent intraocular surgery including verteporfin photodynamic therapy (PDT),
transpupillary thermotherapy, macular translocation, vitrectomy, laser
photocoagulation in macular area, other surgery in macular area or surgery to treat
AMD.

11. Previous extraocular or periocular surgery within 1 month or intraocular surgery
(except the surgery mentioned in exclusion 10 ,such as cataract surgery, etc.) within
3 months prior to dose 1, or current unhealed wound, moderate or severe ulcer or
fracture in the study eye.

12. Subconjunctival or intraocular use of corticosteroids within 3 months (including
subconjunctival or intraocular long-acting implant within 6 months) prior to dose 1 in
the study eye. Use of systemic corticosteroids for 30 or more consecutive days within
3 months prior to dose 1. Inhaled, nasal or dermal steroids are permitted. Topical
ocular corticosteroids administered for 30 or more consecutive days in the study eye
within 3 months prior to dose 1.

13. Previous systemic anti-VEGF therapy or IVT injection of any anti-VEGF drug into either
eye or other ocular use of anti-VEGF drug within 3 months prior to dose 1.

14. Participated in any drug (other than vitamins and minerals) or device clinical trials
3 months or the duration of 5 half-lives of the study drug (which is longer) before
the first dose and have used the test drug or received device treatment.

15. Pregnancy or lactation, or fertile men or women not willing to use effective
contraception from the day when ICF was signed to at least 6 months following the last
dose of study intervention.

16. Infertile women or men fail to meet either of the following ones: 1) menopause (=12
continuous months of amenorrhea with no identified cause other than menopause before
screening); 2) surgically sterilized.

Fertile women or men fail to meet either of the following ones: 1) women of
childbearing potential must have a negative urine or serum pregnancy test result
within 14 days prior to initiation of the study intervention, and should not
breastfeed. If the urine pregnancy test is positive, it must be confirmed by a serum
pregnancy test; 2) agreement to remain abstinent (refrain from heterosexual
intercourse) or use effective contraceptive methods from signed ICF to at least 6
months following the last dose of study intervention. Effective contraceptive methods
with a failure rate of <1% per year, including bilateral tubal ligation, male
sterilization, established, proper use of hormonal contraceptives that inhibit
ovulation, hormone releasing intrauterine devices (IUDs), and copper IUDs.

17. In the Investigator's judgment, there is evidence of a disease or condition that
contraindicates the use an investigational drug or that might affect interpretation of
the results of the study or render the participant at high risk for treatment
complications (e.g. stroke or myocardial infarction within 6 months prior to dose 1,
uncontrolled hypertension (systolic blood pressure =160 mmHg, or diastolic blood
pressure =100 mmHg), etc.).

18. Uncontrolled diabetes (defined as HbA1c>10.0%).

19. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) is more than
twice the upper limit of normal (ULN), and/or serum creatinine is 1.2 times more than
the ULN, and is clinically significant in the opinion of the Investigator.

20. Abnormal coagulation function: prothrombin time(PT) or International normalized ratio
(INR) = 1.5 ×ULN, or activated partial thromboplastin time (aPTT) =1.5 ×ULN, and is
clinically significant in the opinion of the Investigator.

21. Active disseminated intravascular coagulation and obvious bleeding tendency within 3
months prior to dose 1.

22. Evidence of significant uncontrolled concomitant diseases such as cardiovascular
diseases, nervous system diseases, respiratory system diseases, urinary system
diseases, digestive system diseases and endocrine diseases (e.g., stroke, myocardial
infarction).

23. Current treatment for active systemic infection, or history of recurrent serious
infections.

24. Known active or suspected autoimmune diseases, requiring systemic immunosuppressive
therapy.

25. Positive for syphilis screening test human immunodeficiency virus (HIV) infection or
positive for HIV screening test.

26. Known allergy to any component of the study intervention or history of allergy to
fluorescein or indocyanine green, any anesthetics or antimicrobial agents used during
the course of the study.

27. In the Investigator's judgment, other conditions considered not amenable to this
study.

28. Participant who has been diagnosed to be COVID-19 within 2weeks prior to the first
dose, or still symptomatic from an earlier infection (except symptoms associated with
"Long COVID "), or displaying symptoms consistent with COVID-19 in the absence of a
confirmed Covid-19 infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/03/2025
Actual
Sample size
Target
388
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Lions Eye Institute - Nedlands
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
WA 6009 - Nedlands
Recruitment postcode(s) [2] 0 0
- Melbourne
Recruitment postcode(s) [3] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Mississippi
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Veliko Tarnovo
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Burgas
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Montana
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Stara Zagora
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Varna
Country [26] 0 0
China
State/province [26] 0 0
Gansu
Country [27] 0 0
China
State/province [27] 0 0
Guangdong
Country [28] 0 0
China
State/province [28] 0 0
Henan
Country [29] 0 0
China
State/province [29] 0 0
Jilin
Country [30] 0 0
China
State/province [30] 0 0
Ningxia
Country [31] 0 0
China
State/province [31] 0 0
Shandong
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Shanxi
Country [34] 0 0
Czechia
State/province [34] 0 0
Pardubice
Country [35] 0 0
France
State/province [35] 0 0
Amiens
Country [36] 0 0
France
State/province [36] 0 0
Paris
Country [37] 0 0
Germany
State/province [37] 0 0
Bonn
Country [38] 0 0
Germany
State/province [38] 0 0
Freiburg
Country [39] 0 0
Germany
State/province [39] 0 0
Giessen
Country [40] 0 0
Germany
State/province [40] 0 0
Mainz
Country [41] 0 0
Germany
State/province [41] 0 0
Munster
Country [42] 0 0
Germany
State/province [42] 0 0
Sulzbach
Country [43] 0 0
Hungary
State/province [43] 0 0
Budapest
Country [44] 0 0
Hungary
State/province [44] 0 0
Eger
Country [45] 0 0
Hungary
State/province [45] 0 0
Pecs
Country [46] 0 0
Hungary
State/province [46] 0 0
Pécs
Country [47] 0 0
Hungary
State/province [47] 0 0
Szeged
Country [48] 0 0
Italy
State/province [48] 0 0
Milan
Country [49] 0 0
Italy
State/province [49] 0 0
Rome
Country [50] 0 0
Latvia
State/province [50] 0 0
Riga
Country [51] 0 0
Poland
State/province [51] 0 0
Podlaskie
Country [52] 0 0
Poland
State/province [52] 0 0
WA
Country [53] 0 0
Poland
State/province [53] 0 0
Bydgoszcz
Country [54] 0 0
Poland
State/province [54] 0 0
Katowice
Country [55] 0 0
Poland
State/province [55] 0 0
Kraków
Country [56] 0 0
Poland
State/province [56] 0 0
Lublin
Country [57] 0 0
Poland
State/province [57] 0 0
Poznan
Country [58] 0 0
Poland
State/province [58] 0 0
Tarnowskie Góry
Country [59] 0 0
Poland
State/province [59] 0 0
Tarnów
Country [60] 0 0
Poland
State/province [60] 0 0
Walbrzych
Country [61] 0 0
Poland
State/province [61] 0 0
Warsaw
Country [62] 0 0
Poland
State/province [62] 0 0
Warszawa
Country [63] 0 0
Serbia
State/province [63] 0 0
Belgrade
Country [64] 0 0
Singapore
State/province [64] 0 0
Singapore
Country [65] 0 0
Slovakia
State/province [65] 0 0
Banská Bystrica
Country [66] 0 0
Slovakia
State/province [66] 0 0
Nitra
Country [67] 0 0
Slovakia
State/province [67] 0 0
Nové Zámky
Country [68] 0 0
Slovakia
State/province [68] 0 0
Poprad
Country [69] 0 0
Slovakia
State/province [69] 0 0
Trebišov
Country [70] 0 0
Slovakia
State/province [70] 0 0
Trencianske Teplice
Country [71] 0 0
Slovakia
State/province [71] 0 0
Žilina
Country [72] 0 0
Spain
State/province [72] 0 0
Alicante
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Burjassot
Country [75] 0 0
Spain
State/province [75] 0 0
Cordoba
Country [76] 0 0
Spain
State/province [76] 0 0
Madrid
Country [77] 0 0
Spain
State/province [77] 0 0
Majadahonda
Country [78] 0 0
Spain
State/province [78] 0 0
Oviedo
Country [79] 0 0
Spain
State/province [79] 0 0
Pamplona
Country [80] 0 0
Spain
State/province [80] 0 0
San Sebastián
Country [81] 0 0
Spain
State/province [81] 0 0
Sant Cugat Del Valles
Country [82] 0 0
Spain
State/province [82] 0 0
Sevilla
Country [83] 0 0
Spain
State/province [83] 0 0
Valencia
Country [84] 0 0
Spain
State/province [84] 0 0
Valladolid
Country [85] 0 0
Spain
State/province [85] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Shanghai Henlius Biotech
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will compare the efficacy and safety of HLX04-O administered by intravitreal
injection (IVT) with ranibizumab in patients with active wAMD.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04740671
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04740671